TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair